BACKGROUND: EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) demonstrated that mavacamten, a cardiac myosin inhibitor, improves symptoms, exercise capacity, and left ventricular outflow tract (LVOT) obstruction in patients with obstructive hypertrophic cardiomyopathy (oHCM). OBJECTIVES: The purpose of this study was to evaluate mavacamten's effect on measures of cardiac structure and function and its association with changes in other clinical measures. METHODS: Key echocardiographic parameters from serial echocardiograms over 30 weeks from 251 symptomatic oHCM patients (mavacamten [n = 123], placebo [n = 128]) were assessed in a core laboratory. RESULTS: More patients on mavacamten (80.9%; n = 76 of 94) vs placebo (34.0%; n = 33 of 97) showed complete resolution of mitral valve systolic anterior motion after 30 weeks (difference, 46.8%; P < 0.0001). Mavacamten also improved measures of diastolic function vs placebo, including left atrial volume index (LAVI) (mean ± SD baseline: 40 ± 12 mL/m2 vs 41 ± 14 mL/m2; mean change from baseline of -7.5 mL/m2 [95% CI: -9.0 to -6.1 mL/m2] vs -0.09 mL/m2 [95% CI: -1.6 to 1.5 mL/m2]; P < 0.0001) and lateral E/e' (baseline, 15 ± 6 vs 15 ± 8; change of -3.8 [95% CI: -4.7 to -2.8] vs 0.04 [95% CI: -0.9 to 1.0]; P < 0.0001). Among mavacamten-treated patients, improvement in resting, Valsalva, and post-exercise LVOT gradients, LAVI, and lateral E/e' was associated with reduction in N-terminal pro-B-type natriuretic peptide (P ≤ 0.03 for all). Reduction in LAVI was associated with improved peak exercise oxygen consumption (P = 0.04). CONCLUSIONS: Mavacamten significantly improved measures of left ventricular diastolic function and systolic anterior motion. Improvement in LVOT obstruction, LAVI, and E/e' was associated with reduction in a biomarker of myocardial wall stress (N-terminal pro-B-type natriuretic peptide). These findings demonstrate improvement in important markers of the pathophysiology of oHCM with mavacamten. (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT03470545).

2nd Department of Internal Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Bluhm Cardiovascular Institute Northwestern University Feinberg School of Medicine Chicago Illinois USA

Cardiomyopathy Unit Azienda Ospedaliera Universitaria Careggi and the University of Florence Florence Italy

Department of Cardiology Thoraxcenter Erasmus Medical Center Rotterdam Rotterdam the Netherlands

Department of Cardiovascular Diseases Mayo Clinic Phoenix Arizona USA

Department of Internal Medicine Section of Cardiovascular Medicine Yale University New Haven Connecticut USA

Division of Cardiovascular Medicine Brigham and Women's Hospital Boston Massachusetts USA

Duke University School of Medicine Durham North Carolina USA

Heart Institute Hadassah University Medical Center Jerusalem Israel

Institute of Cardiovascular Science University College London London United Kingdom

Methodist DeBakey Heart and Vascular Center Houston Texas USA

MyoKardia Inc a wholly owned subsidiary of Bristol Myers Squibb Brisbane California USA

UCSF HCM Center of Excellence University of California San Francisco San Francisco California USA

J Am Coll Cardiol. 2021 Dec 21;78(25):2533-2536. doi: 10.1016/j.jacc.2021.10.025. PubMed

Citace poskytuje Crossref.org

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03470545